{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:51:12Z","timestamp":1790812272000,"version":"4.1.0"},"reference-count":115,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chylomicronemia, defined by fasting triglycerides \u226510\u2005mmol\/L (\u2265885\u2005mg\/dL), has diverse etiologies. When clinical features such as abdominal pain, lipemia retinalis, eruptive xanthomas, hepatosplenomegaly, pancreatitis, or visibly lipemic plasma accompany the biochemical disturbance, the condition is called chylomicronemia syndrome. Subtypes include rare monogenic familial chylomicronemia syndrome (FCS), the more common multifactorial chylomicronemia syndrome (MCS), autoimmune chylomicronemia, and lipodystrophy-associated chylomicronemia. Patients are at risk for acute pancreatitis and sometimes atherosclerotic cardiovascular disease. Accurate diagnosis includes medical history, physical exam, laboratory testing (including plasma apolipoprotein B and the ratio of triglyceride to total cholesterol), clinical scoring systems, as well as selective use of genetic testing when FCS is suspected. In adults, the overwhelming majority of patients with chylomicronemia have MCS and not FCS. Treatment centers on dietary fat restriction, total alcohol avoidance, management of secondary factors, and traditional triglyceride-lowering therapies such as fibrates and omega-3 fatty acids. Acute pancreatitis management requires stabilization, analgesia, supportive care, and preventive management of hypertriglyceridemia. Emerging RNA-based therapies targeting apolipoprotein C-III (eg, volanesorsen, olezarsen, and plozasiran) offer transformative potential for FCS and for some refractory patients with other chylomicronemia subtypes. A multidisciplinary approach\u2014integrating clinical, biochemical, and genetic assessment\u2014guides therapy and reduces pancreatitis risk.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf701","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:34:29Z","timestamp":1767098069000},"page":"845-859","source":"Crossref","is-referenced-by-count":9,"title":["Approach to the Adult Patient with Chylomicronemia"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A","family":"Hegele","sequence":"first","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University , London, ON N6A 5B7 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"1","key":"2026021918532549500_dgaf701-B1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-021-01517-6","article-title":"Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study","volume":"20","author":"Berberich","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"3","key":"2026021918532549500_dgaf701-B2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacl.2025.02.008","article-title":"Epidemiology and longitudinal course of chylomicronemia: insights from NHANES and a large health care system","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2026021918532549500_dgaf701-B3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrg2481","article-title":"Plasma lipoproteins: genetic influences and clinical implications","volume":"10","author":"Hegele","year":"2009","journal-title":"Nat Rev Genet"},{"issue":"8","key":"2026021918532549500_dgaf701-B4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"1","key":"2026021918532549500_dgaf701-B5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"47","key":"2026021918532549500_dgaf701-B6","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"2026021918532549500_dgaf701-B7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocrine Rev"},{"issue":"12","key":"2026021918532549500_dgaf701-B8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jclinpath-2021-207719","article-title":"Hypertriglyceridaemia: an update","volume":"75","author":"Wierzbicki","year":"2022","journal-title":"J Clin Pathol"},{"issue":"5","key":"2026021918532549500_dgaf701-B9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe hypertriglyceridaemia and chylomicronaemia syndrome -causes, clinical presentation, and therapeutic options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"issue":"2","key":"2026021918532549500_dgaf701-B10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0025-7125(16)31430-4","article-title":"Chylomicronemia syndrome","volume":"66","author":"Brunzell","year":"1982","journal-title":"Med Clin North Am"},{"key":"2026021918532549500_dgaf701-B11","first-page":"249","article-title":"Chylomicronemia syndrome","volume":"37","author":"Chait","year":"1992","journal-title":"Adv Intern Med"},{"issue":"1","key":"2026021918532549500_dgaf701-B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2007.10.004","article-title":"Chylomicronemia and the chylomicronemia syndrome: a practical approach to management","volume":"121","author":"Leaf","year":"2008","journal-title":"Am J Med"},{"issue":"9","key":"2026021918532549500_dgaf701-B13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026021918532549500_dgaf701-B14","doi-asserted-by":"crossref","first-page":"593931","DOI":"10.3389\/fendo.2020.593931","article-title":"A comprehensive update on the chylomicronemia syndrome","volume":"11","author":"Goldberg","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026021918532549500_dgaf701-B15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2026021918532549500_dgaf701-B16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4158\/EP-2018-0157","article-title":"Familial chylomicronemia syndrome: a clinical guide for endocrinologists","volume":"24","author":"Falko","year":"2018","journal-title":"Endocr Pract"},{"issue":"1","key":"2026021918532549500_dgaf701-B17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacl.2018.09.007","article-title":"Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence","volume":"13","author":"Chyzhyk","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2026021918532549500_dgaf701-B18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","article-title":"Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis","volume":"30","author":"Chyzhyk","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"2026021918532549500_dgaf701-B19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MED.0000000000000846","article-title":"Multifactorial chylomicronemia syndrome","volume":"31","author":"Chait","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"2026021918532549500_dgaf701-B20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-511X-10-157","article-title":"Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study","volume":"10","author":"Sandhu","year":"2011","journal-title":"Lipids Health Dis"},{"key":"2026021918532549500_dgaf701-B21","doi-asserted-by":"crossref","first-page":"100978","DOI":"10.1016\/j.ajpc.2025.100978","article-title":"Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology","volume":"22","author":"Saadatagah","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"2026021918532549500_dgaf701-B22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000903","article-title":"An overview of persistent chylomicronemia: much more than meets the eye","volume":"32","author":"Larouche","year":"2025","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2026021918532549500_dgaf701-B23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"key":"2026021918532549500_dgaf701-B24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026021918532549500_dgaf701-B25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/genes16010055","article-title":"Lipoprotein lipase: structure, function, and genetic variation","volume":"16","author":"Perera","year":"2025","journal-title":"Genes (Basel)"},{"issue":"1","key":"2026021918532549500_dgaf701-B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2019.05.023","article-title":"GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism","volume":"30","author":"Young","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"2026021918532549500_dgaf701-B27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MOL.0000000000000916","article-title":"Genetic variation in apolipoprotein A-V in hypertriglyceridemia","volume":"35","author":"Perera","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"2026021918532549500_dgaf701-B28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2026021918532549500_dgaf701-B29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbalip.2011.10.006","article-title":"Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism","volume":"1821","author":"P\u00e9terfy","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2026021918532549500_dgaf701-B30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2026021918532549500_dgaf701-B31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2026021918532549500_dgaf701-B32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021918532549500_dgaf701-B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"2026021918532549500_dgaf701-B34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"1","key":"2026021918532549500_dgaf701-B35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2026021918532549500_dgaf701-B36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J Intern Med"},{"issue":"1","key":"2026021918532549500_dgaf701-B37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2026021918532549500_dgaf701-B38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2020.11.007","article-title":"Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia","volume":"15","author":"Gill","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2026021918532549500_dgaf701-B39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jacl.2022.11.007","article-title":"The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2026021918532549500_dgaf701-B40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacl.2023.08.003","article-title":"Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2026021918532549500_dgaf701-B41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MOL.0000000000000974","article-title":"What is the phenotype of heterozygous lipoprotein lipase deficiency?","volume":"36","author":"Hegele","year":"2025","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"2026021918532549500_dgaf701-B42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrcardio.2017.91","article-title":"Hypertriglyceridaemia caused by GPIHBP1 autoantibodies","volume":"14","author":"Lim","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"2026021918532549500_dgaf701-B43","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021918532549500_dgaf701-B44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacl.2020.01.012","article-title":"Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies","volume":"14","author":"Ashraf","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2026021918532549500_dgaf701-B45","doi-asserted-by":"crossref","first-page":"103335","DOI":"10.1016\/j.autrev.2024.103695","article-title":"Anti-lipoprotein lipase antibodies: a review","volume":"24","author":"de Carvalho","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2026021918532549500_dgaf701-B46","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1210\/jc.2011-1113","article-title":"Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sj\u00f6gren's syndrome","volume":"96","author":"Ashraf","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026021918532549500_dgaf701-B47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/L20-0327","article-title":"Chylomicronemia from GPIHBP1 autoantibodies successfully treated with rituximab: a case report","volume":"173","author":"Lutz","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026021918532549500_dgaf701-B48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MED.0000000000000695","article-title":"Advances in the care of lipodystrophies","volume":"29","author":"Shamsudeen","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"2026021918532549500_dgaf701-B49","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1210\/clinem\/dgaf103","article-title":"Lipodystrophy severity score to assess disease burden in lipodystrophy","volume":"110","author":"Brown","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918532549500_dgaf701-B50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacl.2021.07.004","article-title":"Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2","volume":"15","author":"Lazarte","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2026021918532549500_dgaf701-B51","first-page":"1085","article-title":"Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia","volume":"19","author":"Hang","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"9","key":"2026021918532549500_dgaf701-B52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11892-022-01485-w","article-title":"Lipodystrophy for the diabetologist\u2014what to look for","volume":"22","author":"Patni","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"4","key":"2026021918532549500_dgaf701-B53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1194\/jlr.D045963","article-title":"LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias","volume":"55","author":"Johansen","year":"2014","journal-title":"J Lipid Res"},{"issue":"1","key":"2026021918532549500_dgaf701-B54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jacl.2020.01.003","article-title":"The polygenic nature of mild-to-moderate hypertriglyceridemia","volume":"14","author":"Dron","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"12","key":"2026021918532549500_dgaf701-B55","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/ATVBAHA.122.318621","article-title":"Is genetic testing in hypertriglyceridemia useful?","volume":"42","author":"Hegele","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2026021918532549500_dgaf701-B56","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1210\/jc.2012-1250","article-title":"Severe hypertriglyceridemia in pregnancy","volume":"97","author":"Goldberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021918532549500_dgaf701-B57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2018.12.010","article-title":"Hypothesis II: the majority of VLDL-apoB48 remnants in postprandial plasma are derived from the liver, not from the intestine","volume":"490","author":"Nakajima","year":"2019","journal-title":"Clin Chim Acta"},{"key":"2026021918532549500_dgaf701-B58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cca.2019.05.004","article-title":"The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins","volume":"495","author":"Nakajima","year":"2019","journal-title":"Clin Chim Acta"},{"key":"2026021918532549500_dgaf701-B59","doi-asserted-by":"crossref","first-page":"1322869","DOI":"10.3389\/fendo.2023.1322869","article-title":"The chylomicron saga: time to focus on postprandial metabolism","volume":"14","author":"Gugliucci","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"19","key":"2026021918532549500_dgaf701-B60","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1073\/pnas.88.19.8342","article-title":"Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein","volume":"88","author":"Beisiegel","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026021918532549500_dgaf701-B61","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1172\/JCI107334","article-title":"Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man","volume":"52","author":"Brunzell","year":"1973","journal-title":"J Clin Invest"},{"issue":"5","key":"2026021918532549500_dgaf701-B62","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2026021918532549500_dgaf701-B63","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"12","key":"2026021918532549500_dgaf701-B64","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O\u2019Dea","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026021918532549500_dgaf701-B65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"2026021918532549500_dgaf701-B66","doi-asserted-by":"crossref","first-page":"E1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026021918532549500_dgaf701-B67","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","volume":"110","author":"Spagnuolo","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026021918532549500_dgaf701-B68","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1161\/ATVBAHA.124.320955","article-title":"Ethnic diversity and distinctive features of familial versus multifactorial chylomicronemia syndrome: insights from the UK FCS National Registry","volume":"44","author":"Bashir","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2026021918532549500_dgaf701-B69","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"2026021918532549500_dgaf701-B70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/clinchem\/41.1.153","article-title":"Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins","volume":"41","author":"Zilversmit","year":"1995","journal-title":"Clin Chem"},{"issue":"2","key":"2026021918532549500_dgaf701-B71","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MED.0000000000000393","article-title":"Postprandial remnant lipoproteins as targets for the prevention of atherosclerosis","volume":"25","author":"Nakajima","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2026021918532549500_dgaf701-B72","first-page":"1119","article-title":"Neurodegeneration in familial chylomicronemia syndrome","volume":"19","author":"Bashir","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2026021918532549500_dgaf701-B73","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacl.2025.07.008","article-title":"Brief communication: strong concordance of the North American familial chylomicronemia syndrome score with a positive genetic diagnosis in patients from the balance study","volume":"19","author":"Brown","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2026021918532549500_dgaf701-B74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/erc.12.21","article-title":"Diagnosis and treatment of severe hypertriglyceridemia","volume":"10","author":"Viljoen","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"2026021918532549500_dgaf701-B75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"2026021918532549500_dgaf701-B76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2024.2365787","article-title":"Etiology and emerging treatments for familial chylomicronemia syndrome","volume":"19","author":"Spagnuolo","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"2026021918532549500_dgaf701-B77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/ph18020147","article-title":"Current and emerging treatment options for hypertriglyceridemia: state-of-the-art review","volume":"18","author":"Zimodro","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"2026021918532549500_dgaf701-B78","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3111\/13696998.2013.779277","article-title":"Medical resource use and costs associated with chylomicronemia","volume":"16","author":"Gaudet","year":"2013","journal-title":"J Med Econ"},{"issue":"4","key":"2026021918532549500_dgaf701-B79","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"3","key":"2026021918532549500_dgaf701-B80","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2015.12.023","article-title":"Editorial commentary: dietary management of familial chylomicronemia syndrome","volume":"10","author":"Williams","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2026021918532549500_dgaf701-B81","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026021918532549500_dgaf701-B82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nutres.2022.02.001","article-title":"Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study","volume":"101","author":"Fantino","year":"2022","journal-title":"Nutr Res"},{"issue":"2","key":"2026021918532549500_dgaf701-B83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0009-9120(02)00283-7","article-title":"Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase","volume":"35","author":"Al-Shali","year":"2002","journal-title":"Clin Biochem"},{"issue":"4","key":"2026021918532549500_dgaf701-B84","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2026021918532549500_dgaf701-B85","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1210\/jc.2018-00369","article-title":"Orlistat therapy for children with type 1 hyperlipoproteinemia: a randomized clinical trial","volume":"103","author":"Patni","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026021918532549500_dgaf701-B86","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"2026021918532549500_dgaf701-B87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2026021918532549500_dgaf701-B88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefal\u00f9","year":"2022","journal-title":"Atherosclerosis"},{"issue":"8","key":"2026021918532549500_dgaf701-B89","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"2026021918532549500_dgaf701-B90","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918532549500_dgaf701-B91","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Metreleptin-mediated improvements in lipodystrophy in children","volume":"102","author":"Brown","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026021918532549500_dgaf701-B92","first-page":"e634","article-title":"Earlier initiation of metreleptin in generalized lipodystrophy is associated with improved long-term outcomes","volume":"110","author":"Brush","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026021918532549500_dgaf701-B93","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1210\/jc.2018-02787","article-title":"Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG vs LMNA variants","volume":"104","author":"Sekizkardes","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918532549500_dgaf701-B94","first-page":"197","article-title":"A case of familial partial lipodystrophy type 3 (FPLD3) due to PPARG mutation with extreme hypertriglyceridemia responsive to metreleptin","volume":"20","author":"Lambadiari","year":"2021","journal-title":"Hormones (Athens)"},{"key":"2026021918532549500_dgaf701-B95","doi-asserted-by":"crossref","first-page":"119114","DOI":"10.1016\/j.atherosclerosis.2025.119114","article-title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","volume":"403","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"},{"issue":"14","key":"2026021918532549500_dgaf701-B96","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/eurheartj\/ehab890","article-title":"Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?","volume":"43","author":"Hegele","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"2026021918532549500_dgaf701-B97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2026021918532549500_dgaf701-B98","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2026021918532549500_dgaf701-B99","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacl.2024.12.018","article-title":"Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria","volume":"19","author":"Tsimikas","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"19","key":"2026021918532549500_dgaf701-B100","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021918532549500_dgaf701-B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","author":"Marston","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021918532549500_dgaf701-B102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026021918532549500_dgaf701-B103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MOL.0000000000000798","article-title":"Angiopoietin-like proteins and postprandial partitioning of fatty acids","volume":"33","author":"DiDonna","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"2026021918532549500_dgaf701-B104","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2026021918532549500_dgaf701-B105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"10489","key":"2026021918532549500_dgaf701-B106","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"issue":"25","key":"2026021918532549500_dgaf701-B107","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021918532549500_dgaf701-B108","doi-asserted-by":"crossref","first-page":"119235","DOI":"10.1016\/j.atherosclerosis.2025.119235","article-title":"Angiopoietin-like protein inhibitors: promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia","volume":"405","author":"Vahdat-Lasemi","year":"2025","journal-title":"Atherosclerosis"},{"issue":"2","key":"2026021918532549500_dgaf701-B109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOL.0000000000000960","article-title":"Fibroblast growth factor 21: update on genetics and molecular biology","volume":"36","author":"Barros","year":"2025","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"2026021918532549500_dgaf701-B110","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026021918532549500_dgaf701-B111","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/joim.12925","article-title":"Conservative management in hypertriglyceridemia-associated pancreatitis","volume":"286","author":"Berberich","year":"2019","journal-title":"J Intern Med"},{"issue":"6","key":"2026021918532549500_dgaf701-B112","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(25)00028-2","article-title":"Futility of plasmapheresis, insulin in normoglycaemic individuals, or heparin in the treatment of hypertriglyceridaemia-induced acute pancreatitis","volume":"13","author":"Syed-Abdul","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026021918532549500_dgaf701-B113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-020-0669-2","article-title":"Six years\u2019 experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias","volume":"13","author":"Dron","year":"2020","journal-title":"BMC Med Genomics"},{"issue":"8","key":"2026021918532549500_dgaf701-B114","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/ATVBAHA.120.314168","article-title":"Loss-of-function CREB3L3 variants in patients with severe hypertriglyceridemia","volume":"40","author":"Dron","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2026021918532549500_dgaf701-B115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","article-title":"Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia","volume":"34","author":"Hang","year":"2023","journal-title":"Curr Opin Lipidol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf701\/66168759\/dgaf701.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/845\/66168759\/dgaf701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/845\/66168759\/dgaf701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:53:47Z","timestamp":1771545227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/3\/845\/8407532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":115,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf701","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,31]]}}}